Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: Seeking Alpha
The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competitor Ionis is suing for infringement of its '333 patent. Ionis' olezarsen recently generated very strong phase 3 results in severe hypertriglyceridemia patients and these results offer positive read-through for plozasiran's phase 3 trial with data in mid-2026. Upcoming obesity trial results for ARO-INHBE and ARO-ALK7 and of Wave Life Sciences' INHBE candidate WVE-007 could validate novel mechanisms for fat loss. ARWR's financial position is robust, bolstered by recent deals and milestone payments, reducing the likelihood of future equity raises, especially if plozasiran launches successfully. baona/E+ via Getty Images Arrowhead Pharmaceuticals ARWR ) has a busy schedule in the next few weeks. The PDUFA date for plozasiran for the treatment of familiar chylomicronemia syndrome (‘FCS') is tomorrow, fiscal Q4 2025 results are expected next week, and we should More on my IG s
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]Seeking Alpha
- Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]Yahoo! Finance
- WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]Yahoo! Finance
- WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
- WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.MarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 11/17/25 - Form 8-K
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- WVE's page on the SEC website